Wayrilz (Rezabrutinib) is a Bruton's Tyrosine Kinase inhibitor, first approved in the United States in 2025. It is primarily indicated for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adults who have had an inadequate response to previous treatments. As a novel targeted therapeutic agent, its clinical application must strictly comply with medication guidelines and monitoring requirements.
Precautions for Wayrilz (Rezabrutinib) Administration
Important Limitations
This medication is not indicated for pediatric patients aged 17 years and younger.
It is not indicated for rescue treatment of acute ITP episodes.
Use must be avoided in patients with moderate to severe hepatic impairment and severe renal impairment.
Baseline Testing Items
Verification of female fertility status: Before initiating Rezabrutinib treatment, the pregnancy status of women of reproductive potential must be confirmed.
Baseline assessment of liver function: Measure bilirubin and transaminase levels.
Assessment of infection risk: Conduct a comprehensive evaluation of the patient’s current infection status.
Screening for Special Populations
Women of reproductive potential need to undergo pregnancy testing.
Use should be avoided in patients with moderate to severe hepatic impairment.
Use should be avoided in patients with severe renal impairment.
Management of Special Situations
Gastrointestinal symptoms: When diarrhea, nausea, or abdominal pain occurs, taking the medication with food can improve tolerability.
Missed dose: The missed dose should be taken as soon as possible on the same day, with an interval of at least 2 hours from the next regularly scheduled dose.
Monitoring for Wayrilz (Rezabrutinib) Administration
Infection Risk Monitoring
Increased risk of severe infections: Bacterial, viral, or fungal infections may occur.
Key clinical monitoring points: Closely observe for signs and symptoms of infection, including pneumonia, COVID-19 infection, wound infection, and urinary tract infection.
Response measures: Conduct timely assessment and provide appropriate treatment.
Hematological Monitoring
Neutropenia: In clinical trials, 11% of patients developed Grade 1 or Grade 2 neutropenia.
Patient Education on Symptom Monitoring
Signs of infection: Fever, chills, or flu-like symptoms.
Signs of hepatotoxicity: Abdominal discomfort, dark or "tea-colored" urine, yellowing of the skin or the whites of the eyes.
